Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afuresertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 12/20 | 0.98 |
| ▸ | AKT2 known ✓ | P31751 | 5/20 | 0.98 |
| ▸ | AKT3 known ✓ | Q9Y243 | 5/20 | 0.98 |
| ▸ | PRKCA | P17252 | 3/20 | 0.98 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.98 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.98 |
| ▸ | PRKCB | P05771 | 2/20 | 0.98 |
| ▸ | PRKACA | P17612 | 2/20 | 0.98 |
| ▸ | PRKACB | P22694 | 2/20 | 0.98 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.98 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | LATS1 | O95835 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | PRKCH | P24723 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afuresertib SCHEMBL29432553 | 1.00 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL23858298 | 1.00 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL187686 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL29360487 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL15020961 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL25062435 | 0.92 | AKT1 (0.87) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL1529379 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL1529676 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL27791709 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL12143222 | 0.91 | AKT1 (0.84) | AKT1AKT2AKT3PRKCAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177352-A1 | COMBINATION TREATMENT FOR CANCER | LAEKNA LTD (CN) | 2025-06-05 | — | — | US | claimed |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2024-04-11 | — | — | US | claimed |
| CN-117729923-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4288057-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| EP-4242206-A1 | CRYSTALLINE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHENYL)METHYL]ETHYL}-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE | Novartis AG (CH) | 2023-09-13 | — | — | EP | claimed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | claimed |
| EP-3052098-B1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2020-12-02 | — | — | EP | claimed |
| US-20140073679-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | GLAXOSMITHKLINE LLC (US) | 2014-03-13 | — | — | US | claimed |
| US-8609711-B2 | Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | claimed |
| US-20130288984-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2013-10-31 | — | — | US | claimed |
| US-20130237554-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2013-09-12 | — | — | US | claimed |
| US-20130072507-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2013-03-21 | — | — | US | claimed |
| US-20120283278-A1 | COMBINATION | GLAXO GROUP LIMITED (GB) | 2012-11-08 | — | — | US | claimed |
| US-20120258933-A1 | COMBINATION | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | claimed |
| US-20120202835-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-09 | — | — | US | claimed |
| US-20110288142-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | claimed |
| US-20100197754-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197754-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | PIK3CD, PIK3CA, PIK3CB | AKT1 16/4885AKT2 8/4885AKT3 14/4885 |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | DUSP6, SOS1, DUSP1 | AKT1 50/4885AKT2 42/4885AKT3 119/4885 |
| US-20140073679-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | PIK3CD, PIK3CA, PIK3CB | AKT1 16/4885AKT2 8/4885AKT3 14/4885 |
| US-20130072507-A1 | COMBINATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLCO1B3, QDPR | AKT1 4047/4885AKT2 3607/4885AKT3 3678/4885 |
| US-20120202835-A1 | COMBINATION | PAICS, FOLH1, DHFR | AKT1 4281/4885AKT2 3546/4885AKT3 3945/4885 |
| US-20130237554-A1 | COMBINATION | TPMT, NUP205, MGMT | AKT1 4196/4885AKT2 3171/4885AKT3 3911/4885 |
| US-20110288142-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | PIK3CD, PIK3CA, PIK3CB | AKT1 16/4885AKT2 8/4885AKT3 14/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | AKT1 2381/4885AKT2 1783/4885AKT3 1677/4885 |
| US-20250177352-A1 | COMBINATION TREATMENT FOR CANCER | CD274, PDCD1LG2, PDCD1 | AKT1 3656/4885AKT2 1981/4885AKT3 1572/4885 |
| US-20130288984-A1 | COMBINATION | PSMB5, PSMA5, PSME3 | AKT1 3811/4885AKT2 3318/4885AKT3 3395/4885 |
| US-20120258933-A1 | COMBINATION | PSMB5, PSMA5, PSME3 | AKT1 3811/4885AKT2 3318/4885AKT3 3395/4885 |
| US-20120283278-A1 | COMBINATION | PAICS, SLC10A1, NUP205 | AKT1 3912/4885AKT2 3424/4885AKT3 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.